# Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis

> **NCT06961188** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 174 (estimated)

## Conditions studied

- Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity
- Untreated With Systemic Therapy

## Interventions

- **DRUG:** Nano-crystalline Megestrol Acetate Oral Suspension
- **OTHER:** Standard Therapy

## Key facts

- **NCT ID:** NCT06961188
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2025-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06961188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06961188, "Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06961188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*